6.
Galvin S, Cohen M
. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol. 2004; 2(1):33-42.
DOI: 10.1038/nrmicro794.
View
7.
Jenness S, Weiss K, Goodreau S, Gift T, Chesson H, Hoover K
. Incidence of Gonorrhea and Chlamydia Following Human Immunodeficiency Virus Preexposure Prophylaxis Among Men Who Have Sex With Men: A Modeling Study. Clin Infect Dis. 2017; 65(5):712-718.
PMC: 5848234.
DOI: 10.1093/cid/cix439.
View
8.
Adams L, Kennedy S, Allen L, Barnes A, Bias T, Crane D
. Innovative Solutions for State Medicaid Programs to Leverage Their Data, Build Their Analytic Capacity, and Create Evidence-Based Policy. EGEMS (Wash DC). 2019; 7(1):41.
PMC: 6688544.
DOI: 10.5334/egems.311.
View
9.
Quaife M, MacGregor L, Ong J, Gafos M, Torres-Rueda S, Grant H
. Risk compensation and STI incidence in PrEP programmes. Lancet HIV. 2019; 7(4):e222-e223.
DOI: 10.1016/S2352-3018(19)30333-9.
View
10.
Traeger M, Schroeder S, Wright E, Hellard M, Cornelisse V, Doyle J
. Effects of Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection on Sexual Risk Behavior in Men Who Have Sex With Men: A Systematic Review and Meta-analysis. Clin Infect Dis. 2018; 67(5):676-686.
DOI: 10.1093/cid/ciy182.
View
11.
Smith D, Van Handel M, Grey J
. Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race/ethnicity, United States, 2015. Ann Epidemiol. 2018; 28(12):850-857.e9.
DOI: 10.1016/j.annepidem.2018.05.003.
View
12.
Wu H, Mendoza M, Huang Y, Hayes T, Smith D, Hoover K
. Uptake of HIV Preexposure Prophylaxis Among Commercially Insured Persons-United States, 2010-2014. Clin Infect Dis. 2016; 64(2):144-149.
DOI: 10.1093/cid/ciw701.
View
13.
Sullivan P, Mena L, Elopre L, Siegler A
. Implementation Strategies to Increase PrEP Uptake in the South. Curr HIV/AIDS Rep. 2019; 16(4):259-269.
PMC: 7117066.
DOI: 10.1007/s11904-019-00447-4.
View
14.
Chan S, Chappel A, Joynt Maddox K, Hoover K, Huang Y, Zhu W
. Pre-exposure prophylaxis for preventing acquisition of HIV: A cross-sectional study of patients, prescribers, uptake, and spending in the United States, 2015-2016. PLoS Med. 2020; 17(4):e1003072.
PMC: 7147726.
DOI: 10.1371/journal.pmed.1003072.
View
15.
Tao G, Pearson W, Sullivan J, Henk H, Gift T
. Sexually Transmitted Infection Testing and Prevalence Before and After Preexposure Prophylaxis Initiation Among Men Aged ≥18 Years in US Private Settings. Sex Transm Dis. 2021; 48(7):515-520.
DOI: 10.1097/OLQ.0000000000001339.
View
16.
Owens D, Davidson K, Krist A, Barry M, Cabana M, Caughey A
. Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement. JAMA. 2019; 321(22):2203-2213.
DOI: 10.1001/jama.2019.6390.
View
17.
Donohue J, Jarlenski M, Kim J, Tang L, Ahrens K, Allen L
. Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018. JAMA. 2021; 326(2):154-164.
PMC: 8278273.
DOI: 10.1001/jama.2021.7374.
View
18.
Chang B, Pearson W, Owusu-Edusei Jr K
. Correlates of county-level nonviral sexually transmitted infection hot spots in the US: application of hot spot analysis and spatial logistic regression. Ann Epidemiol. 2017; 27(4):231-237.
DOI: 10.1016/j.annepidem.2017.02.004.
View
19.
Kay E, Pinto R
. Is Insurance a Barrier to HIV Preexposure Prophylaxis? Clarifying the Issue. Am J Public Health. 2019; 110(1):61-64.
PMC: 6893325.
DOI: 10.2105/AJPH.2019.305389.
View
20.
Adimora A, Schoenbach V
. Social context, sexual networks, and racial disparities in rates of sexually transmitted infections. J Infect Dis. 2005; 191 Suppl 1:S115-22.
DOI: 10.1086/425280.
View